<!DOCTYPE html>
<html manifest="manifest.manifest">
<head>
	<meta http-equiv=Content-Type content="text/html; charset=utf-8">
	<title>MRCG Clinical Guidelines</title>
	<meta name="viewport" content="width=device-width, initial-scale=1.0, minimum-scale=1.0, maximum-scale=2.0, user-scalable=1">
  
	<meta name=Generator content="Microsoft Word 14 (filtered)">
	<link rel="manifest" href="/manifest.json">	
<link rel="stylesheet" href="jquery.mobile-1.4.5.min.css" />
	<link rel="stylesheet" href="mystyle.css" />
	<script src="jquery-1.11.1.min.js"></script>
	<script src="jquery.mobile-1.4.5.min.js"></script>
	<script type="text/javascript" src="cordova.js"></script>
	<script>
	    		$(function(){
			$("[data-role='header'], [data-role='footer']").toolbar();
		});
  	  $(document).one('pagebeforecreate', function () {
	        $('input[data-type="search"]').val("");
	    	        $.get("panel.html", function (data2) {
            $.mobile.pageContainer.prepend(data2);
              $("[data-role=panel]").panel().enhanceWithin();
        }, "html");
	           $.get("header.html", function (data) {
      $.mobile.pageContainer.prepend(data);
      $("[data-role='header']").toolbar().enhanceWithin();
    }, "html");
    $.get("footer.html", function (data) {
      $.mobile.pageContainer.append(data);
      $("[data-role='footer']").toolbar().enhanceWithin();
    }, "html");
        $('.WordSection1').wrap('<div role="main" class="ui-content">');
        $('table').wrap('<div class="tableCont"></div>');
        $('img').wrap('<div class="tableCont"></div>');
        $.mobile.pageContainer.enhanceWithin();
	  });
	        $(document).bind( "pagechange", function( ) {
        $('table').wrap('<div class="tableCont"></div>');
        $('img').wrap('<div class="tableCont"></div>');
        $('.tableCont').enhanceWithin();
      } );
			// When the user scrolls down 20px from the top of the document, show the button
		window.onscroll = function() {scrollFunction()};
		function scrollFunction() {
		  if (document.body.scrollTop > 20 || document.documentElement.scrollTop > 20) {
			document.getElementById("myBtn").style.display = "block";
		  } else {
			document.getElementById("myBtn").style.display = "none";
		  }
		}
		// When the user clicks on the button, scroll to the top of the document
		function topFunction() {
		  document.body.scrollTop = 0; // For Safari
		  document.documentElement.scrollTop = 0; // For Chrome, Firefox, IE and Opera
		}</script>      
	





	







  
  
  	
</head>
<body lang=EN-GB link=blue vlink=purple>
	
<div data-role="page">
	<div role="main" class="ui-content">
<div class=WordSection1>
<h1><span lang=EN-US>Hyperthyroidism and goitre</span></h1>
<h2><i><span lang=EN-US>Executive review</span></i></h2>
<h2><span lang=EN-US>Introduction</span></h2>
<p class=MsoNormal><span lang=EN-US>Hyperthyroidism and goitre in The Gambia
are most often caused either by Grave’s disease or by nodular disease. As
everywhere, thyroid disease is more common in women than in men. </span></p>
<p class=MsoNormal><span lang=EN-US>Nodular disease is probably linked to
chronic iodine deficiency and is more common in older patients. It may or may
not be associated with hyperthyroidism.</span></p>
<h3><span lang=EN-US style='font-size:12.0pt;text-decoration:none'>Target User</span></h3>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Nurses</span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Doctors</span></p>
<h3><span lang=EN-US style='font-size:12.0pt;text-decoration:none'>Target area
of use </span></h3>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Outpatient department</span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Ward</span></p>
<h3><span lang=EN-US style='font-size:12.0pt;text-decoration:none'>Key areas of
focus / New additions / Changes.</span></h3>
<p class=MsoNormal><span lang=EN-US>This guideline addresses the diagnosis and management
of hyperthyroidism and goitre.</span></p>
<h3><span lang=EN-US style='font-size:12.0pt;text-decoration:none'>Limitations </span></h3>
<p class=MsoNormal><span lang=EN-US>There is limited availability of an
alternative to carbimazole in the country.</span></p>
<p class=MsoNormal><span lang=EN-US>Thyroidectomy is only available when
skilled surgeons visit The Gambia. There is no access to radioiodine treatment.</span></p>
<span lang=EN-US style='font-size:11.0pt;font-family:"Arial","sans-serif"'><br
clear=all style='page-break-before:always'>
</span>
<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
lang=EN-US style='font-size:12.0pt'>&nbsp;</span></b></p>
<h2><span lang=EN-US>Presenting symptoms and signs</span></h2>
<p class=MsoNormal><span lang=EN-US>Goitre is a common presenting symptom of
thyroid disease. </span></p>
<p class=MsoNormal><span lang=EN-US>Other symptoms related to hyperthyroidism
include:</span></p>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Unintentional weight loss (despite increased
appetite)</span> (although a few patients may gain weight, if excessive intake
outstrips weight loss)</p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Shakiness</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Nervousness</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Anxiety</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Increased perspiration</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Heat intolerance</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Palpitations</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Chest pain – often occurs in the absence of cardiovascular
disease</p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span>Frequent bowel movements</p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Reduction in menstrual flow or oligomenorrhea</span></p>
<p class=MsoNormal><span lang=EN-US>Elderly patients may have only
cardiovascular symptoms, commonly new onset atrial fibrillation</span>.</p>
<p class=MsoNormal><span lang=EN-US>Patients with Grave’s disease may also
present with eye disease (proptosis, periorbital oedema, diplopia) and may have
a past medical history of autoimmune disease (such as rheumatoid arthritis,
vitiligo etc).</span></p>
<h2><span lang=EN-US>Examination findings</span></h2>
<h3><span lang=EN-US>General examination</span></h3>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Raised HR or AF</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Hypertension – with wide pulse pressure</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Warm moist, smooth skin, </span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Lid lag, staring appearance</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Tremor</span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Muscle weakness</span></p>
<h3><span lang=EN-US>Thyroid</span></h3>
<p class=MsoNormal><span lang=EN-US>In Grave’s disease, the thyroid is
typically diffusely enlarged and firm. Multinodular goitres are softer, but may
be much larger. Pain is very unusual.</span></p>
<h2><span lang=EN-US>Differential diagnoses</span></h2>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Anxiety Disorders</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Panic Disorder</span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Withdrawal Syndromes</span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Delirium Tremens (DTs)</span></p>
<span lang=EN-US style='font-size:11.0pt;font-family:"Arial","sans-serif"'><br
clear=all style='page-break-before:always'>
</span>
<p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
lang=EN-US style='font-size:12.0pt'>&nbsp;</span></b></p>
<h2><span lang=EN-US>Investigations</span></h2>
<p class=MsoNormal><span lang=EN-US>US of neck is essential to identify
nodules.</span></p>
<p class=MsoNormal><span lang=EN-US>ECG </span>may show sinus tachycardia or
atrial fibrillation (especially in elderly patients).</p>
<p class=MsoNormal><span lang=EN-US>The most reliable screening measure of
thyroid function is the thyroid-stimulating hormone (TSH) level.
Hyperthyroidism is confirmed by the presence of a TSH level which is</span> low
or <span lang=EN-US>suppressed to</span><span lang=EN-US> </span><span
lang=EN-US>unmeasurable levels (except in the case of secondary hyperthyroidism
due to pituitary disease, which is not considered in this guideline).</span></p>
<p class=MsoNormal><span lang=EN-US>If the TSH is low, then order free T<sub>3</sub>
and free T<sub>4</sub> at the next appointment. The diagnosis is confirmed if
these are raised. Sub-clinical hyperthyroidism is defined as a decreased but
not undetectable TSH level (&lt; 0.5 &#956;IU/mL) in combination with serum
concentrations of T<sub>3</sub> and T<sub>4</sub> that are within the reference
range.</span></p>
<h2><span lang=EN-US>Management </span></h2>
<h2><u><span lang=EN-US>Non-toxic goitre</span></u></h2>
<p class=MsoNormal><span lang=EN-US>This does not usually need any immediate
treatment. Encourage the patient to use iodised salt. If the goitre is large or
the patient is distressed, then consider referral to the surgeons at KGH as
they sometimes have a team of visiting thyroid surgeons.</span></p>
<p class=MsoNormal><b><u><span lang=EN-US>Hyperthyroidism.</span></u></b></p>
<p class=MsoNormal><span lang=EN-US>Once hyperthyroidism is confirmed by a low
TSH, it becomes necessary to check free T<sub>4</sub> and T<sub>3</sub> (fT<sub>3</sub>,
fT<sub>4</sub>). Also check FBC and LFTs.</span></p>
<p class=MsoNormal><u><span lang=EN-US>Initial treatment</span></u></p>
<p class=MsoNormal><span lang=EN-US>Start </span></p>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>adults with HR &gt; 90 on Propranolol 40 mg TDS.</span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>children with HR &gt; 100 and cardiovascular
symptoms on Propranolol 0.5-1.0 mg/kg TDS.</span></p>
<p class=MsoNormal><span lang=EN-US>Once the fT<sub>4</sub> is available, start
Carbimazole as outlined in the table below.</span></p>
<div class="tableCont">
  <table class=MsoTableGrid border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr>
  <td width=192 valign=top style='width:143.8pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-US>fT<sub>4</sub></span></b></p>
  </td>
  <td width=192 valign=top style='width:143.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-US>Adult dose</span></b></p>
  </td>
  <td width=192 valign=top style='width:143.85pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><b><span lang=EN-US>Children’s dose</span></b></p>
  </td>
 </tr>
 <tr>
  <td width=192 valign=top style='width:143.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>1.85 – 2.78 ng/dl</span></p>
  </td>
  <td width=192 valign=top style='width:143.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>5-10 mg OD</span></p>
  </td>
  <td width=192 valign=top style='width:143.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>0.25 mg/kg OD</span></p>
  </td>
 </tr>
 <tr>
  <td width=192 valign=top style='width:143.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>2.78 – 3.7 ng/dl</span></p>
  </td>
  <td width=192 valign=top style='width:143.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>10-20 mg OD</span></p>
  </td>
  <td width=192 valign=top style='width:143.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>0.5 mg/kg OD</span></p>
  </td>
 </tr>
 <tr>
  <td width=192 valign=top style='width:143.8pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>3.7 – 5.55 ng/dl</span></p>
  </td>
  <td width=192 valign=top style='width:143.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>30-40 mg OD</span></p>
  </td>
  <td width=192 valign=top style='width:143.85pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt'>
  <p class=MsoNormal><span lang=EN-US>0.75 mg/kg OD</span></p>
  </td>
 </tr>
</table>
</div>
<p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>
<p class=MsoNormal><span lang=EN-US>Recheck fT<sub>3</sub> and fT<sub>4 </sub>(but
not TSH which is slow to normalize) 1 month after starting treatment. Once the
levels of both are normal, reduce Carbimazole dose by 50% and then recheck
again in 6/52. </span></p>
<p class=MsoNormal><u><span lang=EN-US>Maintenance</span></u></p>
<p class=MsoNormal><span lang=EN-US>Once the patient is euthyroid and stable on
a maintenance dose of Carbimazole (typically 10 mg OD in adults), check the fT<sub>3</sub>,
fT<sub>4</sub> every 3/12. Stop the propranolol. </span></p>
<p class=MsoNormal><span lang=EN-US>Carbimazole is associated with a 1 in 1000
risk of agranulocytosis and a 3 in 10000 risk of liver failure. </span></p>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Warn the patient to return urgently if they
develop a febrile illness, pharyngitis, itchy rash, jaundice, change of colour
of stool or urine, abdominal pain or bloating, anorexia, nausea or vomiting. </span></p>
<p class=MsoListParagraphCxSpMiddle style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Check the FBC or LFTs as appropriate in any
patient presenting with these symptoms. </span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>If either have changed from baseline, then you
may need to stop the carbimazole – remembering that there is no alternative
treatment easily available in the Gambia. </span></p>
<p class=MsoNormal><u><span lang=EN-US>Further treatment</span></u></p>
<p class=MsoNormal><span lang=EN-US>Patients with a toxic nodular goitre are
very likely to need surgery once they are euthyroid and should be referred for
this.</span></p>
<p class=MsoNormal><span lang=EN-US>Patients with Grave’s disease who have been
on treatment for 18 months or more may be able to stop treatment and remain in
remission. </span></p>
<p class=MsoListParagraphCxSpFirst style='text-indent:-18.0pt'><span
lang=EN-US style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>Review the patient clinically 1/12 after
stopping treatment. If they are well, review 3 monthly and check TSH, fT<sub>3</sub>,
fT<sub>4</sub> at each appointment until they have been euthyroid off treatment
for 1 year. Then discharge the patient. </span></p>
<p class=MsoListParagraphCxSpLast style='text-indent:-18.0pt'><span lang=EN-US
style='font-family:Symbol'>·<span style='font:7.0pt "Times New Roman"'>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
</span></span><span lang=EN-US>If they develop hyperthyroidism once again, then
reestablish on treatment and, once they are euthyroid, refer for surgery.</span></p>
<h2><span lang=EN-US>Key Issues for Nursing care</span></h2>
<h2><span lang=EN-US style='font-size:11.0pt;font-weight:normal'>Refer all
patients with possible thyroid disease to the doctor. </span></h2>
<h2><span lang=EN-US>References</span></h2>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Erik D Schraga (30
May 2014). &quot;Hyperthyroidism, Thyroid Storm, and Graves Disease&quot;.
Archived from the original on 5 April 2015. Retrieved 20 April 2015.</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Hyperthyroidism&quot;.
www.niddk.nih.gov. July 2012. Archived from the original on 4 April 2015.
Retrieved 2 April 2015.</span></p>
<p class=MsoNormal><span lang=EN-US style='font-size:10.0pt'>Ross et al. 2016
American Thyroid Association Guidelines for Diagnosis and Management of
Hyperthyroidism and Other Causes of Thyrotoxicosis. Thyroid (2016)
26:1343-1421.</span></p>
<div class="tableCont">
  <table class=MsoNormalTable border=1 cellspacing=0 cellpadding=0
 style='border-collapse:collapse;border:none'>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>Written by:</span></b></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Name: Chibuike Okpara</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border:solid windowtext 1.0pt;
  border-left:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Date: 9 June 2018</span></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>Reviewed by:</span></b></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Name: Babatunde Awokola</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Date: 2 July 2018</span></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>Version:</span></b></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>Change history:</span></b></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>Review due date:</span></b></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>1.0</span></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>New document</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>&nbsp;</span></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>2.0</span></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Updated and transferred to new template</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>31 July 2020</span></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>2.1</span></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Executive summary added</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>31 July 2020</span></p>
  </td>
 </tr>
 <tr style='height:1.0pt'>
  <td width=143 valign=bottom style='width:106.95pt;border:solid windowtext 1.0pt;
  border-top:none;padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>Review Comments (<i>if applicable)</i></span></p>
  </td>
  <td width=241 valign=bottom style='width:181.1pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><span
  lang=EN-US>&nbsp;</span></p>
  </td>
  <td width=191 valign=bottom style='width:143.45pt;border-top:none;border-left:
  none;border-bottom:solid windowtext 1.0pt;border-right:solid windowtext 1.0pt;
  padding:0cm 5.4pt 0cm 5.4pt;height:1.0pt'>
  <p class=MsoNormal style='margin-bottom:0cm;margin-bottom:.0001pt'><b><span
  lang=EN-US>&nbsp;</span></b></p>
  </td>
 </tr>
</table>
</div>
<p class=MsoNormal><span lang=EN-US>&nbsp;</span></p>
</div>
</div><!-- /content -->

</div>

</body>
</html>
